1 / 8

FDA Presentation to the Oncologic Drugs Advisory Committee

FDA Presentation to the Oncologic Drugs Advisory Committee. Zevalin ™ Kit manufactured by IDEC Pharmaceuticals BLA 125019 September 11, 2001. Review Committee. Product/Committee Chair: Marjorie Shapiro, Ph.D. Clinical Reviewers: Philippe C. Bishop, M.D. George Mills, M.D.

griselda
Download Presentation

FDA Presentation to the Oncologic Drugs Advisory Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FDA Presentationto theOncologic Drugs Advisory Committee Zevalin™ Kit manufactured by IDEC Pharmaceuticals BLA 125019 September 11, 2001

  2. Review Committee Product/Committee Chair: Marjorie Shapiro, Ph.D. Clinical Reviewers: Philippe C. Bishop, M.D. George Mills, M.D. Biostatistician: Satish C. Misra, Ph.D. Clinical Toxicology/ Pharmacology: Dave Green, Ph.D. Compliance/BIMO: Mary Andrich, M.D. Product Reviewer: Leon Epps, Ph.D. CMC Reviewers: Deborah Trout, B.S. Kevin O’Brien, B.A. Regulatory Project Manager: Michael Noska, M.S.

  3. Characteristics of 2B8 • Murine IgG1, k (Ibritumomab) • anti-CD20 • Manufactured by standard tissue culture and purification procedures • Conjugated with MX-DTPA (tiuxetan) chelate • Ibritumomab tiuxetan packaged in kits for radiolabeling with 111Indium or 90Yttrium (Zevalin™)

  4. CO2H CO2H N N H N CH3 N N H CO2H 2B8 C CO2H CO2H S Ibritumomab tiuxetan Structure mAb Linker/Chelator; MX-DTPA

  5. Zevalin Kit Components • Ibritumomab tiuxetan • 50 mM Sodium Acetate • Formulation buffer • Reaction vial

  6. Preparation of Radiolabeled-Zevalin • Ordering of 111In from approved source • Coordinated ordering of 111In– and 90Y-Zevalin Kits and 90Y through distributor • Final 111In- and 90Y-labeled Zevalin are prepared on site at radiopharmacy

  7. Zevalin Therapy Components • Step 1 • Rituximab • 111In-Zevalin • Step 2 • Rituximab • 90Y-Zevalin

  8. Proposed Indication For the treatment of patients with relapsed or refractory low grade, follicular or CD20+ transformed B cell Non-Hodgkin’s lymphoma (NHL) and rituximab refractory follicular NHL

More Related